Thyrocare Technologies Share Price Today (THYROCARE)
Today’s Thyrocare Stock Read
Thyrocare Technologies is trading down 6.94% at ₹517.2. With a market cap of ₹8,165.18 Cr, it trades at a P/E of 50.10. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
Thyrocare Technologies is trading down 6.94% at ₹517.2. With a market cap of ₹8,165.18 Cr, it trades at a P/E of 50.10. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
Thyrocare Technologies Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Thyrocare Technologies Limited, framed against the sector median so the premium or discount is obvious at a glance.
Thyrocare Technologies Limited trades at a P/E of 50.10× and P/B of 13.94×.
Valuation
Profitability
Growth
Financial Health
Thyrocare Technologies Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Thyrocare Technologies Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Thyrocare Technologies Limited financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Thyrocare Technologies Limited, switchable between annual and quarterly views, consolidated or standalone.
Thyrocare Technologies Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹8,165.18 Cr and reported EPS of ₹10.23.
| Period | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 403 | 433 | 495 | 589 | 527 | 572 | 687 | 829 |
| Other Income | 10 | 8 | 12 | 29 | 8 | 9 | 15 | 17 |
| Total Income | 413 | 441 | 507 | 618 | 535 | 581 | 702 | 846 |
| Cost of Goods Sold (COGS) | 111 | 117 | 164 | 170 | 163 | 167 | 191 | 220 |
| Gross Profit | 292 | 316 | 331 | 419 | 363 | 405 | 496 | 609 |
| +Operating Expenses | 138 | 144 | 159 | 184 | 243 | 268 | 306 | 347 |
| EBITDA | 154 | 173 | 171 | 235 | 120 | 137 | 190 | 262 |
| +Non-Operating Expenses | 27 | 27 | 31 | 36 | 41 | 51 | 58 | 55 |
| Profit Before Tax (PBT) | 137 | 140 | 153 | 228 | 87 | 96 | 147 | 211 |
| +Tax Expense | 53 | 52 | 39 | 52 | 24 | 26 | 55 | 50 |
| Total Profit for Period | 85 | 88 | 113 | 176 | 64 | 69 | 91 | 163 |
| Less: Non-controlling Interests | — | — | — | — | -0 | -1 | -1 | -0 |
| Net Profit (Owner's PAT) | 85 | 88 | 113 | 176 | 64 | 71 | 92 | 163 |
| Earnings Per Share (EPS) | 5.38 | 5.58 | 7.13 | 11.10 | 4.06 | 4.45 | 5.76 | 10.24 |
| Diluted Shares Outstanding (Nos.) | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| +Additional Disclosures | 387 | 412 | 517 | 560 | 613 | 652 | 743 | 850 |
| Sales Growth % | — | 7.52 | 14.18 | 19.05 | -10.56 | 8.58 | 20.19 | 20.61 |
| YoY Sales Growth % | — | 7.52 | 14.18 | 19.05 | -10.56 | 8.58 | 20.19 | 20.61 |
| Material Cost % | 27 | 27 | 33 | 28 | 30 | 29 | 27 | 26 |
| Employee Cost % | 11 | 11 | 12 | 10 | 20 | 19 | 18 | 17 |
| Other Cost % | 24 | 22 | 21 | 21 | 26 | 28 | 26 | 25 |
| OPM % | 38 | 40 | 35 | 40 | 23 | 24 | 28 | 32 |
| Tax % | 39 | 37 | 26 | 23 | 28 | 28 | 37 | 24 |
| Profit Growth % | — | 3.84 | 27.97 | 55.68 | -63.39 | 9.72 | 29.32 | 78.17 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| +Additional Fields | 128 | 141 | 141 | 201 | 81 | 90 | 135 | 203 |
Thyrocare Technologies segment analysis: revenue and profit mix.
Disclosed business segments at Thyrocare Technologies with their share of revenue and profit, switchable between consolidated and standalone reporting.
Thyrocare Technologies discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Thyrocare Technologies Limited.
Our AI distills the core fundamental drivers supporting Thyrocare Technologies Limited, the risks that threaten it, and the exact valuation or growth triggers that should make you re-evaluate.
Thyrocare Technologies Limited's investment case rests on 8 positive markers and 8 flagged concerns drawn from the latest reported filings.
What you're getting.
Robust profitability. OPM 29.90%, ROCE 24.80% indicate efficient operations.
Strong recent growth. Quarterly profit surged 79.90%, sales increased 22.10%.
Healthy financial position. ROE 16.20%, very low debt-to-equity 0.05.
High promoter confidence. Promoter holding stands at a significant 71%.
Low stock volatility. Beta of 0.4563 suggests lower market risk.
What can break it.
High valuation. P/E ratio of 64.77 suggests potential overvaluation.
Declining FII confidence. FII holding decreased from 12.82% to 4.85%.
Historical EPS growth concerns. 3-year EPS -19.67%, 5-year only 0.61%.
Unsustainable dividend payout. TTM payout ratio is very high at 231.80%.
Limited stock liquidity. Low public shareholding (10.61%) could impact trading.
What would change my mind.
Trim if P/E re-rates above 65. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 24%. The operating engine is no longer compounding capital efficiently.
Thyrocare Technologies Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Thyrocare Technologies Limited is highlighted for quick read-across.
Quick Compare
Thyrocare Technologies Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Thyrocare Technologies Limited — derived from the live tape, not yesterday's close.
Thyrocare Technologies Limited last traded at ₹517.2 with an intraday range of ₹512.2–₹558.5 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹517.20| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 639.00 | +121.80 | +23.55% |
| R3 | 592.70 | +75.50 | +14.60% |
| R2 | 575.60 | +58.40 | +11.29% |
| R1 | 546.40 | +29.20 | +5.65% |
| PIVOT | 529.30 | 12.10 | 2.34% |
| CURRENT | 517.20 | — | — |
| S1 | 407.50 | -109.70 | -21.21% |
| S2 | 453.80 | -63.40 | -12.26% |
| S3 | 483.00 | -34.20 | -6.61% |
| S4 | 500.10 | -17.10 | -3.31% |
THYROCARE is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 548.15 ~ 558.5
Trading Below opening range, showing Bearishness
Thyrocare Technologies Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Thyrocare Technologies Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Thyrocare Technologies Limited stood at 55.7% of traded volume, against a 20-day average of 44.4%.
Thyrocare Technologies announcements: results, concalls, ratings, M&A.
Filings Thyrocare Technologies sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Thyrocare Technologies files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 114 documents below.
Disclosure under SEBI Takeover Regulations
Docon Technologies Private Ltd has submitted to the Exchange a copy of disclosure under Regulations, 31(1) and 31(2) of SEBI ( SAST) Regulations,…
Copy of Newspaper Publication
Please find attached herewith copies of Newspaper Publications published on June 05, 2026, in Business Standard (English) and Navshakti (Marathi)
Copy of Newspaper Publication
Please find enclosed herewith copies of Newspaper advertisement published on May 25, 2026 in Business Standard (English) and Pratahkal (Marathi).
Disclosure under SEBI Takeover Regulations
Docon Technologies Private Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of…
Analysts/Institutional Investor Meet/Con. Call Updates
Thyrocare Technologies Limited has informed the Exchange about Transcript
Investor decks & rating reports.
Thyrocare Technologies insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Thyrocare Technologies as reported to SEBI — buying and selling signals from the people who know the business best.
Thyrocare Technologies insider activity below tracks 42 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Priyanka Jagnani Jain | Insider | 30 Mar 2026 | buy | +2.5 K | ₹8.76 L | ₹350.50 |
| Geetanjali Satish Shahane | Insider | 30 Mar 2026 | buy | +1.0 K | ₹3.58 L | ₹358.20 |
| Priyanka Jagnani Jain | Insider | 30 Mar 2026 | buy | +2.5 K | ₹8.76 L | ₹350.50 |
| Geetanjali Satish Shahane | Insider | 30 Mar 2026 | buy | +1.0 K | ₹3.58 L | ₹358.20 |
| Geetanjali Satish Shahane | Insider | 30 Mar 2026 | buy | +1.0 K | ₹3.58 L | ₹358.20 |
| Priyanka Jagnani Jain | Insider | 30 Mar 2026 | buy | +2.5 K | ₹8.76 L | ₹350.50 |
| Geetanjali Satish Shahane | Insider | 30 Mar 2026 | buy | +1.0 K | ₹3.58 L | ₹358.20 |
| Priyanka Jagnani Jain | Insider | 30 Mar 2026 | buy | +2.5 K | ₹8.76 L | ₹350.50 |
| Geetanjali Satish Shahane | Insider | 30 Mar 2026 | buy | +1.0 K | ₹3.58 L | ₹358.20 |
| Priyanka Jagnani Jain | Insider | 30 Mar 2026 | buy | +2.5 K | ₹8.76 L | ₹350.50 |
Thyrocare Technologies dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Thyrocare Technologies has declared, sequenced by announce and record date.
Thyrocare Technologies corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Thyrocare Technologies Limited: business, sector, key facts.
What Thyrocare Technologies Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Thyrocare Technologies Limited operates in the Healthcare Service Provider industry under the Healthcare sector, listed as NSE: THYROCARE, BSE: 539871.
Thyrocare Technologies Limited is a prominent Indian healthcare company specializing in diagnostic testing services. Its primary business revolves around providing a wide range of medical tests to patients, hospitals, and other laboratories across the country. The company’s focus is on early detection and proactive management of various health conditions, contributing to preventative healthcare.
Thyrocare's services encompass a broad spectrum of diagnostic tests, targeting numerous health areas. These include thyroid disorders (the company's namesake), growth and metabolic issues, autoimmune diseases, diabetes, anemia, cardiovascular health concerns, infertility, and a variety of infectious diseases. This comprehensive approach allows for a holistic assessment of patient health, aiding in early diagnosis and subsequent treatment.
The company operates under a three-segment structure: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment forms the core of Thyrocare's business, encompassing the vast majority of its testing portfolio. The Imaging Services segment likely includes diagnostic imaging procedures, although the provided text does not offer specifics. The "Others" segment appears to encompass ancillary products and services, such as the sale of glucometers and glucostrips under the Sugarscan brand, as well as consumables and radiopharmaceutical products.
A significant aspect of Thyrocare's strategy is its Aarogyam brand. This brand offers a suite of wellness and preventive healthcare tests, catering to individuals focused on proactive health maintenance. These profiles of tests are designed to identify potential health risks early on, allowing for timely intervention and improved health outcomes. By offering a range of tests, from specialized diagnostic tests to comprehensive wellness packages, Thyrocare aims to cater to a wide patient base and various healthcare needs.
In summary, Thyrocare Technologies Limited is a vertically integrated diagnostics company focused on providing a comprehensive suite of testing services aimed at early disease detection and preventive healthcare. Its diverse offerings, including specialized tests, wellness packages, and ancillary products, position it as a major player in the Indian healthcare market. The company's success hinges on its ability to deliver accurate, timely, and cost-effective diagnostic services across a broad range of health conditions.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Health X Platform (HEALTHX) Share PricePeer
- Krsnaa Diagnostics (KRSNAA) Share PricePeer
- Dr Lal Path Labs (LALPATHLAB) Share PricePeer
- Metropolis Healthcare (METROPOLIS) Share PricePeer
- Suraksha Diagnostic (SURAKSHA) Share PricePeer
- Top Losers TodayScreener
- Other overvalued NSE stocksScreener
- Top quality scorecard stocksScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Thyrocare Technologies Limited (THYROCARE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Thyrocare Technologies Limited (THYROCARE)?
The current share price of Thyrocare Technologies Limited (THYROCARE) is ₹517.2. Today, the stock has declined by ₹38.60 (6.94%), trading in a range of ₹512.2 to ₹558.5. The stock opened at ₹555.8 with a trading volume of 5,03,084 shares.
02Is Thyrocare Technologies Limited stock a good investment for long-term?
Thyrocare Technologies Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹8,165.18 crores, P/E ratio of 50.10, ROE of 28.75%, and ROCE of 35.40%. The dividend yield stands at 1.80%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Thyrocare Technologies Limited stock?
The 52-week high price of Thyrocare Technologies Limited (THYROCARE) is ₹1,610, while the 52-week low is ₹342.55. Currently trading at ₹517.2, the stock is 13.8% away from its 52-week low and 67.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Thyrocare Technologies Limited stock at the current price?
Whether to buy Thyrocare Technologies Limited stock at ₹517.2 depends on multiple factors. The stock is currently trading with a P/E ratio of 50.10 and P/B ratio of 13.94. Today's performance shows a loss of 6.94%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Thyrocare Technologies Limited and when is the next dividend?
Thyrocare Technologies Limited offers a dividend yield of 1.80%, which means for every ₹100 invested at the current price of ₹517.2, you can expect to receive approximately ₹1.80 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Thyrocare Technologies Limited?
Thyrocare Technologies Limited's key financial metrics include: P/E Ratio: 50.10, P/B Ratio: 13.94, ROE: 28.75%, ROCE: 35.40%, Dividend Yield: 1.80%, EPS: ₹10.23, Book Value: ₹33.6, and Debt-to-Equity: 0.09. The company's market cap stands at ₹8,165.18 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Thyrocare Technologies Limited stock performing today in the market?
Thyrocare Technologies Limited stock opened at ₹555.8 and is currently trading at ₹517.2, showing a decline of ₹38.60 (6.94%). The intraday high is ₹558.5 and low is ₹512.2. The trading volume stands at 5,03,084 shares, indicating moderate market participation today.
08What is the P/E ratio of Thyrocare Technologies Limited and what does it indicate?
Thyrocare Technologies Limited has a Price-to-Earnings (P/E) ratio of 50.10, which means investors are willing to pay ₹50.10 for every ₹1 of earnings. With an EPS of ₹10.23, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Thyrocare Technologies Limited (THYROCARE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.